Autres langues HUTCHMED (China) Limited

Actions

HCM

KYG4672N1198

Marché Fermé - London S.E. Autres places de cotation 17:35:22 23/04/2024			Varia. 5j.	Varia. 1 janv.
290 ^GBX	+5,07 %		+8,21 %	+2,47 %

05/04	Hutchmed présentera de nouvelles données à la conférence américaine sur la recherche sur le cancer	MT
05/04	HUTCHMED (China) Limited souligne les données qui seront présentées au Congrès 2024 de l'AACR	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Hutchmed to Present New Data at US Cancer Research Conference	05/04
HUTCHMED Limited Highlights Data to be Presented at AACR Congress 2024	05/04
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status	03/04
Hutchmed endometrial cancer treatment application accepted for review	02/04
Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination	02/04
HSBC in special payout on Canada sale; Astra FDA win	02/04
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	02/04
Sector Update: Health Care Stocks Advance Premarket Thursday	28/03
Hutchmed lung cancer treatment accepted for review in China	28/03
Hutchmed Says Supplemental New Drug Application for Savolitinib Accepted for Review in China	28/03
JD Sports backs outlook; Spirent accepts new offer	28/03
Hutchmed (China)'s NDA Application Accepted by Chinese Authorities	28/03
HUTCHMED Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC	28/03
Hutchmed begins registration stage for sovleplenib phase 2/3 trial	22/03
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug	22/03
Hutchmed (China) Initiates Phase II/III Clinical Trials for Autoimmune Disease Drug	22/03
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China	22/03
Hutchmed Initiates Registration Stage of the Eslim-02 Phase Ii/Iii Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China	22/03
Hutchmed Returns to Profit in 2023; EPS Tops Estimate	29/02
EARNINGS: Hutchmed revenue surges, Craven House's loss widens	28/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues HUTCHMED (China) Limited

Actions

HCM

KYG4672N1198

Autres langues

Filtres